<DOC>
	<DOCNO>NCT01796431</DOCNO>
	<brief_summary>The purpose study look level three HIV medication : tenofovir , emtricitabine , rilpivirine blood drug intake stop order understand long drug persist blood . The study specifically look blood level three drug ( take 3-in-1 tablet ) take every day 14 day . The duration subject involvement study 23 day plus screening visit take place 4 week prior start study , follow visit take place 16-22 day last dose study medication . This study randomise mean participant receive study medication order . The participant study doctor know study medication take time study .</brief_summary>
	<brief_title>Pharmacokinetics Tenofovir Tenofovir-diphosphate , Emtricitabine Emtricitabine-triphosphate , Rilpivirine Once Daily Over 14 Days Following Drug Intake Cessation Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Rilpivirine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Subjects must meet follow inclusion criterion within 28 day prior baseline visit : The ability understand sign write informed consent form , prior participation screening procedure must willing comply study requirement Male nonpregnant , nonlactating female Between 18 65 year , inclusive Body Mass Index ( BMI ) 18 35 kg/m2 , inclusive Women childbearing potential ( WOCBP ) must use adequate method contraception avoid pregnancy throughout study period least 12 week study Willing consent personal detail enter onto The Overvolunteering Prevention Scheme ( TOPS ) database Willing provide photographic identification visit Registered GP UK Subjects meet follow exclusion criterion enrol study : Any significant acute chronic medical illness Evidence organ dysfunction clinically significant deviation normal physical examination , vital sign , ECG clinical laboratory determination Positive blood screen hepatitis B surface antigen and/or C antibody Positive blood screen HIV1 and/or 2 antibody Current recent ( within 3 month ) gastrointestinal disease Known allergy lactose monohydrate , sunset yellow aluminium lake ( E110 ) , patient galactose intolerance , Lapp lactase deficiency , glucosegalactose malabsorption Clinically relevant alcohol drug use ( positive urine drug screen ) history alcohol drug use consider Investigator sufficient hinder compliance treatment , followup procedure evaluation adverse event . Smoking permit , tobacco intake remain consistent throughout study Exposure investigational drug placebo within 3 month first dose study drug Use drug ( unless approve Investigator ) , include overthecounter medication herbal preparation , within two week prior first dose study drug , unless approved/prescribed Principal Investigator know interact study drug . Females childbearing potential without use effective nonhormonal birth control method , willing continue practise birth control method least 12 week end treatment period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>